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ABSTRACT 
Goals of Work:  Multiple sites enable more successful completion of adequately powered phase 
III studies in palliative care. Audits of the frequency and distribution of the symptoms of interest 
can better inform research planning by determining realistic recruitment goals for each site. The 
proposed studies are to improve the evidence-base for registration and subsidy applications for 
frequently encountered symptoms where current pharmacological interventions are being used 
‘off-licence’. 
 
Methods:  Six services participated in a standardized, retrospective, consecutive cohort audit of 
five symptoms of their inpatient populations to inform the design of double blind randomised 
controlled phase III studies to which each site would recruit simultaneously. The audit covered 
all deaths in a three month period for people who were referred to a specialist palliative care 
service who had at least one inpatient admission between referral and death regardless of when 
the person was referred to the service. The audits were based around inclusion and exclusion 
criteria for the proposed studies.  
 
Main Results: Of the 468 people whose medical records were reviewed, potential study 
participant rates varied by symptom having accounted for general and specific inclusion and 
exclusion criteria: pain 17.7%; delirium 5.8%; anorexia 5.1%; bowel obstruction 2.8% and 
cholestatic itch 0%. For those people with a symptom of interest, it was noted at the beginning of 
the inpatient admission more than half the time. Of all inpatients, fewer then one third would be 
eligible to participate in at least one study.  
 
Conclusions: These data provide a baseline estimate of potential people to approach about 
clinical trials in supportive care but do not account for clinician ‘gate-keeping’, lack of interest in 
participating nor withdrawal from the study once initiated. The data are retrospective and 
therefore limited by clinical documentation. The audit directly informed an increase in the 
number of participating sites.  
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INTRODUCTION 
Large scale trials in supportive, palliative and hospice care are feasible, especially if protocols 
can be designed appropriately for use in several sites simultaneously [6]. One reason for the 
failure of many studies in palliative care is an over-estimation of likely recruitment even for 
frequently encountered symptoms. A more comprehensive understanding of patterns of symptom 
occurrence for each participating site (given local variations in referral patterns) and general 
factors that may affect potential phase III study participation in a supportive and palliative care 
population need to be included in feasibility assessment. The design needs to take careful 
account of such findings if studies are going to be successful, and key performance indicators for 
each site can be tailored to local symptom patterns to monitor trial progress. 
 
Rigorous phase III studies need to be undertaken to widen existing medication registration 
criteria (clinical indication, target population, formulation, route of administration) and to 
demonstrate cost effectiveness for subsidy applications in supportive and palliative care. The 
Australian Government has provided funds for a national multi-site Palliative Care Clinical 
Studies research Collaborative (PaCCSC) to undertake a series of phase III studies to improve 
the evidence base for the use of key symptom control medications and evaluate their cost-
effectiveness across the community. [18] The medications chosen in this process defined the 
symptoms that are audited in this report. There is an expectation that PaCCSC will also be a 
catalyst for capacity building to improve clinical research capability in supportive and palliative 
care nationally and improve the way cost-effectiveness is analysed in this population. All the 
studies have been designed to meet CONSORT guidelines [12] and achieve the highest possible 
Jadad scores [13], while also using standardised toxicity reporting (National Cancer Institute 
common terminology criteria) and measurement tools validated in the study population for 
primary end points [4].  
 
The PaCCSC collaborative research team encompasses key skills in supportive and palliative 
care clinical trials research, clinical pharmacology, pharmaco-economics, biostatistics and drug 
regulatory affairs. The research team is overseen by a national Management Advisory Board, and 
supported by a Scientific Committee providing an internal peer review process for trial 
development. A Trial Management Committee with representatives from each trial and each 
participating site oversees the development and execution of individual studies.   
 
Participating sites represent the diversity of models of supportive and palliative care service 
provision in metropolitan Australia. PaCCSC sites vary in terms of size, sources of referrals, 
resources, and the local clinical team’s experience with, and attitudes towards clinical trials. This 
variety of service settings helps to optimise the generalizability of any subsequent findings [1] 
but may limit the ability of each site to recruit to each study at the same rate.  
 
Audit methodology has been used by researchers in other disciplines conducting multi-site 
studies to determine a site’s ability to recruit to specific studies [19]. The aim of this paper is to 
describe a multi-site, retrospective consecutive cohort feasibility audit of five symptoms of 
interest and its implications for the phase III randomised controlled trials that will be run 
subsequently. 
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PATIENTS AND METHODS 
Development of the audit.  The audit was developed to determine the frequency with which 
symptoms of interest occurred in the clinical services, and the likely proportion of people who 
would meet general and study-specific eligibility criteria for the proposed phase III studies. 
Symptom frequencies were sought for complex pain (that has not responded to appropriate 
combination therapy), anorexia, acute confusion / delirium, malignant bowel obstruction and 
cholestatic itch. The audit was developed from draft protocols for each phase III study under 
consideration by clinical trialists, a research statistician, health economist and a clinical 
pharmacist.   
 
Study setting 
Six specialist palliative care services drawn from all mainland states of Australia were involved, 
having competed for participation in PaCCSC.  These sites had demonstrated experience in 
randomised controlled trials and were a combination of ‘consultation only’ teaching hospital 
services (n=1), regional services encompassing inpatient, outpatient and community services 
(n=3), and those with inpatient and consult services (n=2). All sites for the audit were 
metropolitan services with people with cancer as the predominant referral source. (Table 1) 
 
Participants: A consecutive cohort of all people who died within a three month period (where 
the most recent death was at least six months before the audit to allow time for the collation of 
all relevant medical records) and had at least one inpatient admission between referral and death 
(as studies were to be for inpatients only) was generated by each of the six PaCCSC sites (Figure 
1). The inpatient admission needed to have formally involved the supportive and palliative care 
service (either as direct care, shared care or consultative input). The audit did not include people 
only referred for community support who were not admitted to hospital between referral and 
death. 
 
Data Collection: The retrospective chart review of clinical care data was conducted in the second 
half of 2007. A project officer with an appropriate health-related background was employed for 3 
months to conduct the audit at each site.  From the medical records of the service (inpatient, 
outpatient and community care) and the health services through which care was provided, patient 
demographics, primary diagnosis, reasons for referral to the specialist palliative service, reasons 
for admission to an in-patient unit (where the first admission after referral to the specialist 
palliative care service was used for data collection), functional status, prevalence of symptoms 
and medication use during the first hospital admission were recorded. Data both at the time of, 
and during the course of this admission were captured in the audit. Data were collected from 
routine clinical records with services using a variety of ways of capturing data, none of which 
was the same between the participating services.  
 
A comprehensive data collection guide and glossary were developed to ensure consistent coding 
across all sites. Training and support was provided nationally to assist the project officers coding 
and entering the data. Key definitional issues included prevalent symptoms (those present on 
admission to the inpatient unit), incident symptoms (those symptoms that occurred or recurred 
during the person’s inpatient stay) and the distinction between general criteria for inclusion / 
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exclusion (those common to all studies and related to global abilities to participate in clinical 
trials) and those specific to individual studies. (Table 4) 
 
Data management.  Data were recorded on paper-based case report forms and then entered 
electronically onto a password protected, web-based access database (www.caresearch.com.au).  
Each new record with completed data uploaded on the web system generated an automatic email 
to the coordinating site to enable real time checking of data against copied source records before 
the new file was merged into the master database. As expected, there were missing data, and 
these fields in the audit were left blank.  
 
Ethics approval.  The symptom audit was deemed a quality assurance exercise by the sites’ 
respective Human Research Ethics Committees (HREC). All data were de-identified and 
aggregated for each site. Permission was granted by all HRECs to publish the outcomes of the 
audit.  
 
RESULTS 
Characteristics of potential participants 
A total of 468 deaths occurred in the six services in a three months period where the deceased 
had at least one admission to an inpatient unit between referral and death. (Table 1) Of these 
people, 66% were male, and 54% were aged 65 or older at the time of the audit. Eighty percent 
of admissions were initiated because of symptom control. Eleven percent (n= 53) of individuals 
did not have English as their first language and required an interpreter, a key general inclusion 
criterion for participation where validated study tools were not available in the person’s usual 
language. 
 
The number of inpatient admissions for participating services each month ranged from 15 to 92 
people. The main sources of referral for the services were for people already hospitalised.  The 
most frequently encountered diagnosis was lung cancer, (Table 2) and pain, dyspnoea, nausea 
and vomiting, and caregiver needs were the most frequently cited reasons for referral to the 
services.   
 
Two hundred and thirty two (50%) people had performance status recorded in 4 sites. The 
Eastern Cooperative Group (ECOG) measure was used in 144 cases and the Australian-modified 
Karnofsky Performance Scale (AKPS) in 88. Overall performance status was poor with 75% 
having an AKPS of 50 or less, or 72% an ECOG score of 2 or greater.   
 
Evaluation of symptoms 
Both the prevalence of symptoms on admission and the incidence of that symptom occurring for 
the first time or reoccurring during the admission were coded. Between 50% and 91% of all 
occurrences of a symptom of interest were present on admission to the inpatient unit. (Table 3) 
 
Eligibility factors 
All general and study specific reasons for trial eligibility and ineligibility are outlined in Table 4.   
 
Frequency of a person qualifying for a study 
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Individual studies had potential participation rates varying between 0% (cholestatic itch) and 
62% (malignant bowel obstruction) if the symptom was present either on or during an admission. 
(Table 3). Of the 468 people whose medical records were reviewed, potential study participant 
rates varied by symptom having accounted for general and specific inclusion and exclusion 
criteria: pain 17.7%; delirium 5.8%; anorexia 5.1%; bowel obstruction 2.8% and cholestatic itch 
0%. (Table 3) Of the 468 people with a palliative diagnosis who had their clinical records 
examined, a total of 134 (29%) would have met eligibility criteria. Of these people, 117 (88%) 
would have qualified for one study, 16 (12%) for two studies and 1 (1%) for three or more of the 
proposed studies.  
  
DISCUSSION 
There is a continuing ethical imperative to improve the clinical evidence for quality supportive 
and palliative care in areas that are of relevance to patients and their caregivers [17]. This audit, 
in preparing for a series of adequately powered phase III studies with embedded patient-defined 
clinical outcomes and cost-effectiveness analyses, provides a unique basis for estimating the 
population of potential participants. Such research aims to improve the quality of care by 
measuring the net clinical effect of pharmacological interventions in clinical presentations in 
supportive and palliative care incorporating the benefits and toxicities. As each of the 
medications being studied through PaCCSC is out of patent, public funding is an appropriate 
way to do this research. To achieve such an ambitious program of work, trial design needs to be 
informed by as much information in the planning stage as possible. 
 
What data are supported by the current study? 
This audit provided a snapshot of the patient population in a number of inpatient clinical settings 
around Australia and found that 29% of people were potentially eligible to participate in the 
target clinical studies. The total symptom prevalence patterns (including those symptoms 
prevalent on inpatient admission and those that developed or recurred during the inpatient stay) 
were similar to that of other audits conducted in supportive and palliative care [20]. A systematic 
review of symptom prevalence in the last weeks of life found that 5 symptoms, (fatigue, pain, 
lack of energy, weakness and anorexia) occurred in more than 50% of all people [21]. The 
findings are also consistent with the data on the reasons that referral to specialized supportive 
and palliative care services occurs [14].   
 
The clinical conditions being studied fit into two general categories – those that can occur 
consistently with advanced disease often presenting with an insidious onset where prevalence is 
crucial (pain, anorexia) and those that are less likely to occur but often precipitate unexpected 
changes in care where incidence is more important (delirium, bowel obstruction). Both general 
criteria (inability to complete study questionnaires, poor cognition, and poor performance status) 
and specific inclusion and exclusion criteria for each symptom were evaluated in the audit.  
 
Given that 12% of potentially eligible people could theoretically participate in two or more 
studies, there is the need to understand from the data in this audit which studies are likely to have 
the most difficulty recruiting. It is important to prioritise participation in studies where 
enrollment rates are likely to be lower. 
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There are a number of factors in the literature that will affect the participation in supportive and 
palliative care clinical studies that cannot be estimated from the audit. These include reasons that 
people do not want to participate in any study [3,23] and clinicians who will not refer an 
apparently eligible person to study staff [10,22]. Other factors such as staff enthusiasm and the 
underlying (lack of) research culture for each participating clinical unit will be of relevance to 
final participation rates. 
 
Monitoring of trials will need to consider key performance indicators including the rates at 
which, and reasons people decline to participate in the study, withdraw from a study between 
consent and randomization, or between randomization and completion [5,11,15]. These 
considerations will influence recruitment and retention strategies.  Although in these studies it is 
not expected that there will be high rates of withdrawal as a consequence of the study itself, there 
will be people who withdraw as they become too frail to continue participation.  
 
The studies have been designed as effectiveness studies including the widest possible group of 
participants (in contrast to a highly selected sub-population in an efficacy study). Despite this, up 
to 28% of people referred to the services with a symptom of interest are not even likely to meet 
general eligibility criteria. The majority of people are unable to participate because of the very 
poor functional status, which is also reflected in the relatively low discharge rate back to the 
community in some of the participating inpatient units. 
 
Direct modifications to study design / conduct as a result of the audit 
Given the complexity of running a multi-site study in any population, it is important that each 
site understands the performance criteria for its continued participation in the collaborative. This 
audit has helped to set realistic goals for each study in each site by establishing the baseline 
practice in which the studies will be conducted. As some of the variations between sites can be 
explained by the referral-dependent nature of supportive and palliative care, key performance 
indicators (KPIs) tailored to each site based on its referral patterns have resulted from the audit. 
 
Study design was refined as a result of the audit by: 
- defining two studies that would need more recruiting sites to meet timelines; 
- identifying objectively sites that would be unable to recruit effectively to one or more studies; 
- identifying that some studies are likely to accrue participants more slowly, requiring protocols 
to ensure every single potential participant is identified systematically; and  
- changing the studies from running sequentially to simultaneously given the small numbers of 
potential participants who had more than one symptom of interest.  
 
A crucial finding that is still to be fully implemented in each site is that in more than one in two 
people, the symptom of interest was present at the time of admission to the inpatient unit. (Table 
3) As such, adequate screening at admission for eligibility becomes an imperative process to 
institute. 
 
Other collateral benefits of the audit 
It is difficult to bring together palliative clinicians, researchers and policy makers for such an 
ambitious program of research, especially when some of the researchers had been competitors 
for very limited palliative care research funds in the recent past. The audit allowed the committee 
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structure of the collaborative to establish its processes away from the pressure of the actual 
clinical studies.  The audit provided an opportunity for each site to start to work collaboratively 
with the national coordinating centre and to finalise and test the Standard Operating Procedures 
and online data entry systems.  It also allowed the national coordinating centre to start working 
with each site, its research ethics committee and their clinicians.  
 
The audit allowed the inclusion and exclusion criteria of each study to be critically tested and 
refined in the light of the clinical settings in which the studies are being conducted. The audit 
also encouraged sites to identify and engage with other clinical units in their institutions whose 
patients could be eligible for the studies.     
 
Limitations - Methods 
As with any retrospective chart review, there are significant limitations as they only allow 
information that has been recorded to be collected [8]. The audit highlighted the lack of 
documentation of key data variables of interest. For example, only one half of the people had 
functional status recorded in their clinical records despite this being a patient-valued metric, and 
a surprisingly small proportion of patients had anorexia documented. These data elements are 
now included in a national benchmarking project which is collecting point of care data on more 
than 75% of all people referred to specialized supportive and palliative care services nationally at 
point of clinical contact [7].This should lead to better levels of comparable documentation fields 
in the future.  
 
The symptom of greatest concern was delirium. Most units had no routine screening processes 
despite its prevalence in cancer care [16]. The tools that will be used in the studies (which could 
be reasonably used in clinical practice) will be the Memorial Delirium Assessment Scale [2] and 
the Nursing Delirium Screening scale [9]. No unit was routinely using a screening scale or 
diagnostic tool even when a new episode of delirium was clinically suspected.  
 
The study chose to use deaths and retrospectively assess for study eligibility from the first 
inpatient admission after referral to the palliative care service (Table 3). This ensured the best 
possible longitudinal data for study eligibility at any time after admission. Because only one 
inpatient admission was used for each participant, this may systematically underestimate the 
overall incidence of symptoms of interest given that they may develop at any time along the 
disease trajectory. New inpatient admissions could equally have been the point at which data 
collection started, but for an audit, this would have been more resource intensive, without 
increasing the detail or quality of the data collected.   
 
Limitations - Sample 
The most obvious limitation in the sample is that it did not include patients for whom the 
supportive and palliative care service was being consulted in the community. At least one of the 
studies (malignant bowel obstruction) will now enroll participants in the community if their 
symptoms are uncontrolled. None of the services involved has any particular local relationships 
or referral patterns that differ markedly from the general patterns of referral other than one 
service that has very limited after hours capacity for surgery, potentially limiting the likelihood 
of recruiting to the study on bowel obstruction. 
 
Page 8 of 11 
Archived at Flinders University: dspace.flinders.edu.au
  
Implications for palliative care research more generally 
The most important findings from this audit are that it has helped to foster a new collaborative, 
allowed expansion of site numbers for specific studies and refinement of trial design in order to 
optimise successful outcomes for the phase III studies.  These issues will be judged ultimately by 
successful completion of the definitive studies.  
 
Complete Funding Declaration 
Direct costs of this study were provided through a grant from the Palliative Care Branch of the 
Australian Department of Health and Ageing (Canberra, Australia), under the National Palliative 
Care Strategy.  Flinders University is technically the sponsor organisation for the individual 
studies proposed.  The design, conduct, analysis and write-up of the study were performed 
independently from any funding or sponsoring agency. 
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Figure 1: Illustrative figure of admissions to and death whilst being supported by a 
specialised palliative care service in relation to the audit of potential trial participants. 
Admission to inpatient unit is noted separately. All deaths within a three month period 
became the basis of the audit, irrespective of when a person was referred to the service. 
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Table 1. Demographic and admission data on 468 consecutive admissions to six services across 
Australia for palliative care in a retrospective cohort study. 
7 Sites 
 
Mean 
duration 
referral to 
death 
(median; 
SD; range) 
Days 
Mean 
length of 
inpatient 
admission 
(median; 
SD; range) 
Days 
Mean age 
(Median; 
SD; range) 
 
 
 
Years 
Percentage of population… 
who 
are 
male 
who 
are 
>65 
with 
cancer 
(n) 
who 
required an 
interpreter 
(n)  
A* 
n=78 
30 
(10; 46;  
0-237) 
14 
(11, 10,  
0 -42) 
69 
(72; 14;  
32-93) 
69 53 74 (58) 13 (10) 
B* 
n=30 
87 
(45, 101; 
0-413) 
10 
(6,10, 1-
51) 
65 
(67; 20;  
20-93) 
29 55 87 (26) 3 (1) 
C 
n=83 
170 
(103, 203, 
1-1037) 
28 
(15, 40, 0-
308) 
75 
(80; 14;  
34-96) 
59 56 87 (72) 5 (4) 
D 
n=90 
131 
(26, 503,  
1-4674) 
19 
(16, 16,  
1-93) 
74 
(70; 11;  
34-100) 
68 56 93 (84) 18 (16) 
F 
n=53 
19 
(11,20, 
1-90) 
8 
(8,6,1-24) 
73 
(77, 13,  
38-96) 
75 64 89 (47) 2 (1) 
G 
n=71 
51 
(25, 86,  
1-512) 
15 
(11, 12, 1-
60) 
65 
(65, 15,  
21-89) 
46 54 99 (70) 6 (4) 
H 
n=63 
92 
(60,93,  
0-357) 
14 
(15,10,  
1-31) 
67 
(68, 12,  
37-91) 
56 69 94 (59) 27 (17) 
All 
n = 468 
 
92 
(30; 257; 
0-4674) 
18 
(13; 22; 
0-308) 
69 
(72; 15; 
20-96) 
66 54 89 (416) 11 (53) 
* Sites A and B were two teaching hospital inpatient campuses of the same regional palliative care service 
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Table 2. The three most frequently encountered life-limiting illnesses for each audited site 
from a consecutive, multi-site, retrospective cohort study evaluating potential phase III 
symptom control clinical trial participation.  
7 Sites 
n=468 
1 2 3 
A* 
n=78 
Lung cancer 
12 (16%) 
Other GIT cancer 
12 (16%) 
Unknown primary  
11 (15%) 
B* 
n=30 
Lung cancer 
5 (17%) 
Colo-rectal cancer 
4 (14%) 
Heart failure 
4 (14%) 
C 
n=83 
Lung cancer 
24 (29%) 
Heart failure 
24 (29%) 
Respiratory failure 
17 (21%) 
D 
n=90 
Lung cancer 
18 (20%) 
Other GIT cancer 
12 (14%) 
Colo-rectal cancer 
10 (12%) 
F 
n=53 
Lung cancer 
13 (25%) 
Prostate cancer 
9 (17%) 
Pancreatic cancer 
6 (12%) 
G 
n=71 
Lung cancer 
24 (34%) 
Head and Neck cancer 
8 (12%) 
Other GIT cancer 
7 (10%) 
H 
n=63 
Lung cancer 
14 (23%) 
Other GIT cancer 
11 (18%) 
Breast cancer 
6 (10%) 
* Sites A and B were two teaching hospital inpatient campuses of the same regional palliative 
care service 
 
  
Table 3: Likely eligibility of a consecutive, retrospective multi-site cohort of 468 people with life-
limiting illnesses admitted to seven inpatient units for potential participation in clinical studies. 
Column number; Cn 
C1 C2 C3 C4 C5 C6 C7 
Symptom / 
sign 
Prevalence - 
present on 
admission;  
Symptom is 
present on 
admission as 
a percentage 
of all people 
who  have 
the symptom 
at any time 
(C2/C4)*100 
Incidence - 
developed 
or recurred 
during 
admission 
 
 
Symptom 
present at 
any time 
(on or after 
admission)
* 
Broadly 
eligible for 
PaCCSC 
studies;  
 
(C5/C4)*100;   
 
Dominant 
reason for 
broad 
ineligibility 
Specifically 
eligible for a 
PaCCSC 
study with this 
symptom 
present at 
some time;  
 
(C6/C4)*100; 
 
Dominant 
reason for 
specific 
ineligibility 
Overall 
eligibility in 
the cohort 
 
 
 
 
 
(C6/468)*100 
Pain -  199 
 (84%) 
126 237 200 
(85%) 
 
Incapable of 
complying with 
study 
procedures 
83 
(35%)  
 
Planned 
chemotherapy/r
adiotherapy 
17.7% 
Delirium 39 
 (53%) 
59 73 66**  
(90%) 
 
Difficulty 
swallowing 
27** 
(37%) 
 
Anti-psychotic 
medication use 
5.8% 
Anorexia 127 
 (91%) 
85 140 101  
(72%) 
 
Performance 
status 
24  
(17%) 
 
Glucocorticoid 
use 
5.1% 
Bowel 
obstruction 
secondary to 
malignancy 
18 
 (86%) 
11 21 21^^ 
(100%) 
 
13  
(62%) 
 
Planned 
surgery 
2.8% 
Cholestatic 
itch 
1  
(50%) 
2 2 2  
(100%) 
 
0  
(0%) 
 
Ondansetron 
use 
0 
None 75 29 29    
Not stated 41 15 15    
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* Numbers with the condition "Any Time" may be less than the sum of "On Admission" and 
"During Admission" as a patient may have had the condition on admission, had it resolve and 
again developed the problem during the admission. 
** Does not include specific assessment of the Memorial Delirium Assessment Score nor the 
Nursing Delirium Assessment scores as these were not routinely collected in any of the 
participating sites before the study 
^^ Excludes vomiting 
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Table 4 – General and study specific inclusion and exclusion criteria for clinical studies  
 Inclusion criteria Exclusion criteria 
General 
 Palliative diagnosis 
Prognosis sufficient to warrant entry into 
the study* 
Over 18 years of age 
Proficiency in English sufficient to 
complete the study measures 
Mini-Mental State Examination >23 
Able to comply with study procedures 
Able to give written informed consent (or 
has an appropriate proxy) 
Previous documented adverse reaction to any of the study 
medications 
Unable to comply with study procedures 
Currently (or recently) on the study medication 
Participation in a study with a new chemical entity in the 
previous month 
Women who are pregnant, lactating or have not had 
adequate advice about birth control if fertile 
Study-specific 
Pain - Chronic pain related to cancer or its 
treatment 
Brief Pain Inventory >3 in the previous 
24 hours 
- Stable opioids for last 48 hours with the 
intention for stable opioids for the next 5 
days 
- Likely to be inpatient for 5 days 
- Adequate trial of relevant co-analgesics  
- Exposure to ketamine in the previous six months  
- Radiotherapy to painful sites recent or planned 
- Chemotherapy or hormone therapy started within the last 
month 
- History of psychoses, acute intermittent porphyria, 
uncontrolled hyperthyroidism, uncontrolled epilepsy, 
uncontrolled hypertension. Uncontrolled raised intraocular 
pressure, recent alcohol or illicit drug misuse or recent use 
of mono amine oxidase inhibitors 
Delirium - DSM IVR1 diagnostic criteria for 
delirium 
MDAS2 ≥ 7  
- NuDesc3 score of 1 on questions 2 
and/or 3 and/or 4 
- Likely to be inpatient for 4 days 
- Able to take oral solution 
- availability of an acceptable proxy to 
give consent 
- Delirium due to withdrawal from medications or alcohol 
- History of neuroleptic malignant syndrome, 
extrapyramidal disorders including Parkinson’s or 
prolonged QT syndrome 
- Antipsychotic use in the last week 
- Cerebrovascular accident or seizure in the last month 
Anorexia - Self-reported loss of appetite for at least 
2 weeks on numerical rating scale of 4 or 
less (0 = no appetite) 
- Able to take and absorb oral 
medications 
- anti-depressants, antipsychotics and 
omega 3 fatty acids stable for at least one 
month 
- History or proven thromboembolic disease or long-term 
vascular access device without adequate anticoagulation 
- Use of glucocorticoids or progestogens, androgens, 
cannabinoids, olanzapine, psychostimulants 
-Tube feeding or parenteral nutrition 
- Clinically significant ascites 
- poorly controlled NYHA4 grade IV heart failure or 
uncontrolled hypertension 
- unmonitored diabetes mellitus 
- uncontrolled diarrhoea, nausea or vomiting 
- active systemic infection at the study start. 
Bowel 
obstruction  
- Vomiting as a result of a bowel 
obstruction that necessitates a change in 
clinical management 
- Advanced cancer where therapy is 
unlikely to change the clinical course  
- Australian-modified Karnofsky performance score of 
<30 at beginning of trial 
- Calculated creatinine clearance <10ml/min 
- Clinically significant cirrhosis 
- Venting or feeding gastrostomy / jejunostomy 
- Bowel surgery planned within the next 72 hours 
Cholestatic 
itch 
- Self –reported itch 3 or more on a 0-10 
rating scale not responding to current 
treatment 
- Recent use of ondansetron 
- History of uncontrolled constipation 
- History of uncontrolled headaches 
* Varied on the duration of the proposed studies 
1 Diagnostic and Statistical Manual of Mental Disorders, fourth edition revised 
2 Memorial Delirium Assessment Scale 
3 Nursing Delirium Screening Scale 
4 New York Heart Association 
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